Capital World Investors lifted its position in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) by 1.4% in the fourth quarter, Holdings Channel reports. The institutional investor owned 1,433,094 shares of the medical research company’s stock after acquiring an additional 20,371 shares during the quarter. Capital World Investors’ holdings in Natera were worth $328,308,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in the stock. Westfield Capital Management Co. LP increased its stake in Natera by 24.1% in the fourth quarter. Westfield Capital Management Co. LP now owns 714,692 shares of the medical research company’s stock valued at $163,729,000 after purchasing an additional 138,890 shares during the period. Vise Technologies Inc. acquired a new stake in shares of Natera in the fourth quarter worth $356,000. Daiwa Securities Group Inc. grew its holdings in Natera by 0.9% during the 4th quarter. Daiwa Securities Group Inc. now owns 13,028 shares of the medical research company’s stock valued at $2,985,000 after purchasing an additional 119 shares in the last quarter. TD Asset Management Inc grew its holdings in Natera by 21.5% during the 4th quarter. TD Asset Management Inc now owns 157,466 shares of the medical research company’s stock valued at $36,074,000 after purchasing an additional 27,860 shares in the last quarter. Finally, Sivia Capital Partners LLC increased its stake in Natera by 73.8% during the 4th quarter. Sivia Capital Partners LLC now owns 2,440 shares of the medical research company’s stock valued at $559,000 after buying an additional 1,036 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.
Analyst Upgrades and Downgrades
A number of analysts have issued reports on NTRA shares. The Goldman Sachs Group assumed coverage on shares of Natera in a research note on Friday. They issued a “neutral” rating and a $245.00 target price for the company. Robert W. Baird set a $265.00 target price on shares of Natera in a research report on Friday, May 8th. Wall Street Zen lowered shares of Natera from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. William Blair started coverage on shares of Natera in a report on Tuesday, April 14th. They issued an “outperform” rating on the stock. Finally, Wolfe Research started coverage on shares of Natera in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $260.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $256.12.
Natera Stock Down 0.9%
Natera stock opened at $213.47 on Tuesday. The stock has a market cap of $30.57 billion, a PE ratio of -130.96 and a beta of 1.56. The business’s 50-day moving average price is $204.53 and its two-hundred day moving average price is $216.13. Natera, Inc. has a 12-month low of $131.81 and a 12-month high of $256.36.
Insider Buying and Selling at Natera
In other news, insider Solomon Moshkevich sold 3,000 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $218.43, for a total transaction of $655,290.00. Following the transaction, the insider owned 137,643 shares of the company’s stock, valued at $30,065,360.49. This represents a 2.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Steven Leonard Chapman sold 41,124 shares of the stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $221.03, for a total value of $9,089,637.72. Following the sale, the chief executive officer directly owned 108,743 shares in the company, valued at $24,035,465.29. This trade represents a 27.44% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 148,500 shares of company stock valued at $32,274,898 in the last three months. Insiders own 5.05% of the company’s stock.
Natera Profile
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Featured Articles
- Five stocks we like better than Natera
- 3 Stocks With Fresh Catalysts to Watch Before the July 4
- Amprius Insiders Are Selling: Should Investors Be Worried?
- A Weaker Dollar Could Put These 3 Industrial Stocks Back in Focus
- A Market Rotation Toward Quality Will Benefit These 3 ETFs
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
